36. Epidermolysis bullosa Clinical trials / Disease details
Clinical trials : 160 / Drugs : 195 - (DrugBank : 47) / Drug target genes : 50 - Drug target pathways : 124
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04917874 (ClinicalTrials.gov) | May 25, 2021 | 2/6/2021 | A Long-term Treatment With B-VEC for Dystrophic Epidermolysis Bullosa | Open Label Treatment of Beremagene Geperpavec (B-VEC) | Dystrophic Epidermolysis Bullosa;DEB - Dystrophic Epidermolysis Bullosa;Recessive Dystrophic Epidermolysis Bullosa;Dominant Dystrophic Epidermolysis Bullosa | Biological: Open Label Topical Beremagene Geperpavec (B-VEC) | Krystal Biotech, Inc. | NULL | Recruiting | 6 Months | N/A | All | 30 | Phase 3 | United States |
| 2 | NCT04491604 (ClinicalTrials.gov) | August 17, 2020 | 22/7/2020 | The Objective of This Study is to Compare the Efficacy and Safety of Beremagene Geperpavec (B-VEC) Topical Gel With That of Placebo for the Treatment of Dystrophic Epidermolysis Bullosa (DEB). | A Phase III Double Blinded, Placebo-Controlled, Efficacy and Safety Study of Beremagene Geperpavec (B-VEC, Previously KB103) for the Treatment of Dystrophic Epidermolysis Bullosa (DEB) | Dystrophic Epidermolysis Bullosa;Recessive Dystrophic Epidermolysis Bullosa;Dominant Dystrophic Epidermolysis Bullosa | Biological: Topical Beremagene Geperpavec;Other: Placebo | Krystal Biotech, Inc. | NULL | Active, not recruiting | 6 Months | N/A | All | 31 | Phase 3 | United States |
| 3 | NCT03536143 (ClinicalTrials.gov) | May 7, 2018 | 20/4/2018 | Topical Beremagene Geperpavec (KB103) Gene Therapy to Restore Functional Collagen VII for the Treatment of Dystrophic Epidermolysis Bullosa | A Phase II Study of Beremagene Geperpavec (KB103), a Non-Integrating, Replication-Incompetent Herpes Simplex Virus 1 (HSV-1) Vector Expressing the Human Collagen VII (COL7) Protein, for the Treatment of Dystrophic Epidermolysis Bullosa (DEB) | Dystrophic Epidermolysis Bullosa | Biological: Topical beremagene geperpavec | Krystal Biotech, Inc. | NULL | Active, not recruiting | 5 Years | N/A | All | 4 | Phase 2 | United States |